Compare Neurocrine Biosciences Inc (NBIX) vs Realty Income Corp (O) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Realty Income Corp — how do they compare? Neurocrine Biosciences Inc trades at $158.44 (market cap $16.46B), while Realty Income Corp trades at $62.18 (market cap $58.56B). The key difference: Realty Income Corp is far larger — about 3.6× Neurocrine Biosciences Inc's market cap, and Realty Income Corp pays a 5.25% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | O | |
|---|---|---|
Market Cap | $16.46B | $58.56B |
Sector | Health | Real Estate |
52-Week High | $185.50 | $67.56 |
52-Week Low | $123.10 | $55.93 |
Enterprise Value | $16.48B | $89.19B |
Dividend Yield | — | 5.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $158.89, down 3.66% in the past 24 hours, reflecting near-term bearish technical signals. The stock shows strong fundamentals with Q2 2026 revenue growth of 39% year-over-year to $959 million and a net income margin of 20.91%. Recent news highlights include positive clinical data for INGREZZA and the initiation of a Phase 1 study for a GLP-1/GIP/glucagon receptor triple agonist, though safety concerns were raised for Vykat XR in Prader-Willi Syndrome.
The outlook remains positive given robust earnings beats, raised 2026 sales guidance, and a consensus price target of $208.82 implying significant upside. Risks include clinical trial setbacks, competitive pressures, and regulatory scrutiny. Analyst sentiment is strongly bullish with 86% buy ratings, supporting a growth-oriented investment case amid near-term volatility.
Realty Income (O) trades at $61.89, down 0.99% for the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported Q2 2026 EPS of $0.37, missing the $0.3977 estimate, but raised full-year AFFO guidance. Recent news highlights a $875 million convertible notes offering and a $6 billion hyperscale data center joint venture, supporting growth initiatives amid a 98.8% portfolio occupancy rate.
Outlook remains supported by dividend growth—115 consecutive quarterly increases—and a $10 billion investment target, though elevated debt levels and interest rate sensitivity pose risks. Analysts maintain a consensus price target of $67.29, implying ~9% upside, with 41% buy ratings reflecting cautious optimism for the REIT's income stability and expansion into data centers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Realty Income Corp
Realty Income owns roughly 11,400 properties, most of which are freestanding, single-tenant, triple-net-leased retail properties. Its properties are located in 49 states and Puerto Rico and are leased to 250 tenants from 47 industries. Recent acquisitions have added industrial, office, manufacturing, and distribution properties, which make up roughly 17% of revenue.
Read more on O →
